Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Medical Biomaterials Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran.
Int J Biol Macromol. 2024 Jun;269(Pt 1):132023. doi: 10.1016/j.ijbiomac.2024.132023. Epub 2024 Apr 30.
Colon cancer is one of the lethal diseases in the world with approximately 700,000 fatalities annually. Nowadays, due to the side effects of existing methods in the treatment of colon cancer such as radiotherapy and chemotherapy, the use of targeted nanocarriers in cancer treatment has received wide attention, and among them, especially liposomes have been studied a lot. Based on this, anti-tumor drugs hidden in targeted active liposomes can selectively act on cancer cells. In this systematic review, the use of various ligands such as folic acid, transferrin, aptamer, hyaluronic acid and cRGD for active targeting of liposomes to achieve improved drug delivery to colon cancer cells has been reviewed. The original articles published in English in the databases of Science Direct, PubMed and Google scholar from 2012 to 2022 were reviewed. From the total of 26,256 published articles, 19 studies met the inclusion criteria. The results of in vitro and in vivo studies have revealed that targeted liposomes lead to increasing the efficacy of anti-cancer agents on colon cancer cells with reducing side effects compared to free drugs and non-targeted liposomes. To the best of our knowledge, this is the first systematic review showing promising results for improvement treatment of colon cancer using targeted liposomes.
结肠癌是世界上致命的疾病之一，每年约有 70 万人因此死亡。如今，由于放疗和化疗等现有结肠癌治疗方法的副作用，癌症治疗中靶向纳米载体的应用受到了广泛关注，其中脂质体的研究较多。基于此，隐藏在靶向活性脂质体中的抗肿瘤药物可以选择性地作用于癌细胞。在这项系统评价中，综述了各种配体（如叶酸、转铁蛋白、适体、透明质酸和 cRGD）用于脂质体的主动靶向，以实现对结肠癌细胞的改良药物传递。检索了 2012 年至 2022 年在 Science Direct、PubMed 和 Google Scholar 数据库中以英文发表的原始文章。在总共 26256 篇已发表的文章中，有 19 项研究符合纳入标准。体外和体内研究的结果表明，与游离药物和非靶向脂质体相比，靶向脂质体使抗癌药物对结肠癌细胞的疗效提高，副作用降低。据我们所知，这是第一项系统评价，表明使用靶向脂质体改善结肠癌治疗具有广阔的前景。
